Erdafitinib as a new targeted therapy option for patients with advanced urothelial cancer

Erdafitinib, as an innovative oral targeted drug, provides a new treatment strategy for patients with specific types of advanced or metastatic urothelial carcinoma (UC). This drug is classified as a multikinase inhibitor and exerts its therapeutic effect by specifically inhibiting tyrosine kinase activity in tumor cells.

After strict review and approval by the U.S. Food and Drug Administration (FDA), erdafitinib is approved to treat patients who meet the following conditions:

1.Progressive urothelial carcinoma: Erdafitinib has become an effective treatment for adult UC patients whose disease has progressed despite chemotherapy. UC, this kind of tumor often occurs in the bladder, ureter and renal pelvis. Although it is uncommon, its risk cannot be ignored.

2.Tumors with FGFR abnormalities: Erdafitinib is particularly suitable for patients with fibroblast growth factor receptor (FGFR) gene abnormalities in urothelial cancer. The FGFR abnormalities here include gene mutations, overexpression or amplification, and such abnormalities are not uncommon in urothelial cancer.

3.Situations that cannot be tolerated or chemotherapy is ineffective: For those patients who cannot tolerate chemotherapy or are ineffective, erdafitinib is like a breath of fresh air, bringing them the possibility of another treatment. This is an important option for patients whose condition is deteriorating and in urgent need of alternative treatment options.

Although the scope of application of erdafitinib is relatively specific, it brings new hope to those patients with specific types of UC, especially those who do not respond to or cannot tolerate traditional treatment methods. However, before starting erdafitinib treatment, genetic testing is an indispensable step to confirm whether the patient's tumor has FGFR abnormalities and to determine whether the drug is suitable. At the same time, regular monitoring during treatment and follow-up with doctors are also key to ensuring treatment effectiveness and patient safety.